The U.S. Food and Drug Administration is in the final stages of reviewing an application from Intrexon Corp.’s Oxitec unit to conduct a field trial in the Florida Keys, Oxitec Chief Executive Officer Hadyn Parry said in a phone interview. Parry wasn’t able to provide further details on the timing of an FDA decision.
Oxitec genetically modifies the males in a breed of mosquito known as Aedes aegypti — responsible for transmitting Zika, Dengue, Chikungunya and Yellow Fever — so that their offspring die young. The Zika virus has been spreading “explosively” in South and Central America, the World Health Organization said Thursday. Developing a vaccine could take years, drugmakers and health experts have cautioned.
from Next Big Future http://ift.tt/1P2XqjE
via IFTTT